Enzene Biosciences Ltd.
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Holding
- Established
- 2006-08-28
- Employees
- 251
- Market Cap
- -
- Website
- http://www.enzene.com
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
Phase 3
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Biological: ProliaBiological: ENZ215
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Enzene Biosciences Ltd.
- Target Recruit Count
- 504
- Registration Number
- NCT05405725
- Locations
- 🇨🇿
MEDICAL PLUS s.r.o., Uherské Hradiště, Czechia
Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers
Phase 1
Recruiting
- Conditions
- Healthy Male Subjects
- Interventions
- Biological: EU Sourced ProliaBiological: ENZ215Biological: US Sourced Prolia
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Enzene Biosciences Ltd.
- Target Recruit Count
- 207
- Registration Number
- NCT05245669
- Locations
- 🇧🇬
MC Comac Medical, Sofia, Sofia City Province, Bulgaria
🇵🇱MTZ Clinical Research powered by Pratia, Pratia S.A, Warszawa, Poland
© Copyright 2025. All Rights Reserved by MedPath